TET2 promoter DNA methylation and expression analysis in pediatric B-cell acute lymphoblastic leukemia

Hematology Reports

Volumn 6, Issue 1, 2014, Pages 19-22

  Musialik, Ewa ^a   Bujko, Mateusz ^a   Wypych, Agnieszka ^b   Matysiak, Michał ^b   Siedlecki, Janusz Aleksander ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

B cell acute lymphoblastic leukemia; DNA methylation; TET2

Indexed keywords

BISULFITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CELLULAR DISTRIBUTION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENETIC CORRELATION; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PROMOTER REGION; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TET2 GENE;

EID: 84897125707     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2014.5333     Document Type: Article

References (20)

1. Ito S, D'Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, EScell self-renewal and inner cell mass specification. Nature 2010;466:1129-33.
2. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-43.
3. Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25-38.
4. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301.
5. Ballestar E, Pérez C, Martínez-Calle N, et al. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One 2012;7: e31605.
6. Langemeijer SMC, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-42.
7. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-7.
8. Kosmider O, Gelsi-Boyer V, Ciudad M, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009;94:1676-81.
9. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24: 1128-38.
10. Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009;114:3285-91.
11. Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010;116:1132-5.
12. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011;29:1373-81.
13. Chou W-C, Chou S-C, Liu C-Y, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011;118:3803-10.
14. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-67.
15. Jankowska AM, Szpurka H, Tiu R V, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403-10.
16. Tefferi A, Pardanani A, Lim K-H, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-11.
17. Viguié F, Aboura A, Bouscary D, et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 2005;19:1411-5.
18. Langemeijer SMC, Jansen JH, Hooijer J, et al. TET2 mutations in childhood leukemia. Leukemia 2011;25:189-92.
19. Kim Y-H, Pierscianek D, Mittelbronn M, et al. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 2011;64:850-2.
20. Chim CS, Wan TS, Fung TK, Wong KF. Methylation of TET2, CBL and CEBPA in Phnegative myeloproliferative neoplasms. J Clin Pathol 2010;63:942-6.